2017年9月18日，上海复星医药 (集团) 股份有限公司 (简称“复星医药”，股份代码: 600196.SH, 02196.HK) 公告称，鉴于Gland Pharma目前经营状况良好，Gland Pharma创始人家族有意在不影响复星医药对Gland Pharma实现控股收购的前提下，对Gland Pharma保留更高的持股比例，新修订的协议将使复星医药和Gland Pharma的管理团队之间形成更紧密的合作关系，以期共同推动Gland Pharma持续稳健发展。经友好协商，拟对Gland Pharma收购方案进行调整，复星医药拟出资不超过109,130万美元收购Gland Pharma约74%的股权，其中包括收购方将依据依诺肝素在美国上市销售所支付的不超过2,500万美元的或有对价。
18 September 2017, Shanghai Fosun Pharmaceutical(Group) Co.,Ltd. (referred to as “Fosun Pharma”) (stock code: 600196.SH,02196.HK) announced today that, as Gland Pharma's operations continue to perform well, the Founder Shareholders propose to maintain a higher stake in Gland Pharma without impacting the acquisition of a controlling interest in Gland Pharma by Fosun Pharma. The revisions to the agreement will establish a closer cooperation between the management teams of Fosun Pharma and Gland Pharma to jointly promote the sustainable and stable development of Gland Pharma. The parties have now reached agreement that Fosun Pharma will acquire an approximate 74% stake in Gland Pharma for no more than US$ 1,091.30 million, including paying no more than US$ 25 million contingent consideration for Gland Pharma's Enoxaparin sales in the U.S. market.
根据公告，复星医药拟收购KKR及创始人股东合计持有的Gland Pharma股权比例由69.971%调整为57.891%。收购完成后，KKR将不再持有Gland Pharma的股权。受让Vetter家族所持股权及购买可转换优先股的数量和金额维持不变；同时，本次交易的终止日将延长至2017年10月3日。
According to the announcement, the stake of Gland Pharma held by KKR Floorline Investment Pte.Ltd. and the Founder Shareholders that will be acquired by Fosun Pharma is adjusted from 69.971% to 57.891%. After the transaction is completed, KKR will no longer own shares in Gland Pharma. The aggregate number of shares held by Vetter Family and the Convertible Shares to be purchased remains unchanged. Atthe same time, the Termination Date shall be extended to 3 October 2017.
Gland Pharma成立于 1978 年，总部位于印度海德拉巴，是印度领先的注射剂仿制药品生产制造企业。Gland Pharma是印度第一家获得美国FDA批准的注射剂药品生产制造企业，并获得全球各大法规市场的GMP认证，其业务收入主要来自于美国和欧洲。Gland Pharma目前主要通过共同开发、引进许可，为全球各大型制药公司提供注射剂仿制药品的生产制造服务等。
Gland Pharmais a leading Indian pure-play generic injectable pharmaceutical products company incorporated in 1978, with its headquarters based in Hyderabad, India. Gland Pharma is the first injectable drugs manufacturer in India which has been approved by the U.S. FDA and has obtained the GMP Certification from major global laws and regulations markets. Its revenue mainly come from the United States and Europe. Currently, Gland Pharma's main business model is joint development of products and introduction of licenses to provide all global major pharmaceutical companies with the manufacturing services in relation to injectable generic drugs.
复星集团联席总裁、复星医药董事长陈启宇表示：“中国和印度在制药领域有很强的互补性。以复星医药和Gland Pharma为代表的中印药企的资源嫁接将有利于推动中国药企在研发创新及仿制药出口等方面的国际化步伐。”
Mr. Chen Qiyu, Co-Presidentof Fosun Group and Chairman of Fosun Pharma said, “China and India have strong complementarities in the field of pharmaceuticals. The resource grafting of Chinese and Indian pharmaceutical companies represented by Fosun Pharma and Gland Pharma will help promote the internationalization of Chinese pharmaceutical companies in R&D innovation and generic drug export, etc.”
Gland Pharma的管理团队相信，与复星医药的合作将促使公司为印度生物医药市场做出更大贡献，并预示着医疗行业强劲的增长前景。除了能加快Gland Pharma公司的发展步伐，这一合作关系还将促进印度制药行业在中长期内创造更多就业机会。
The management team of Gland Pharma believes that the partnership with Fosun Pharma will enable the company to contribute further to the Indian bio-tech market. It also signals strong growth prospects of the healthcare sector overall. In addition to accelerating the investment plans of Gland Pharma, this partnership will facilitate creation of more jobs in the Indian pharmaceutical industry in the medium to long term.
本次交易完成后，将有助于推进复星医药的药品制造业务的产业升级、加速国际化进程、提升在注射剂市场的占有率。同时，复星医药将借助Gland Pharma自身的研发能力及印度市场特有的仿制药政策优势，嫁接复星医药已有的生物医药创新研发能力，实现产品线的整合及协同，从而扩大药品制造与研发业务的规模。
The transaction will promote Fosun Pharma's development by upgrading its drug manufacturing business, accelerating the internationalization process and enhancing Fosun Pharma's market share in the injectables market. The transaction signals the strong growth prospects of the healthcare sector overall. At the same time, Fosun Pharma will arm itself with Gland Pharma's abilities in R&D and the policy advantages in injectables in Indian market, together with the biopharmaceutical innovative R&D capabilities, to integrate production lines and synergize innovation, so as to enlarge the scales in drug manufacturing and R&D.
